159 related articles for article (PubMed ID: 17382387)
21. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.
Gutierrez-Cosío S; de la Rica L; Ballestar E; Santamaría C; Sánchez-Abarca LI; Caballero-Velazquez T; Blanco B; Calderón C; Herrero-Sánchez C; Carrancio S; Ciudad L; Cañizo C; San Miguel JF; Pérez-Simón JA
Leuk Res; 2012 Jul; 36(7):895-9. PubMed ID: 22503131
[TBL] [Abstract][Full Text] [Related]
23. HOXA9 gene expression in the chronic myeloid leukemia progression.
Tedeschi FA; Zalazar FE
Leuk Res; 2006 Nov; 30(11):1453-6. PubMed ID: 16630659
[TBL] [Abstract][Full Text] [Related]
24. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
25. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
26. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
27. Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients.
Bussolari R; Candini O; Colomer D; Corradini F; Guerzoni C; Mariani SA; Cattelani S; Silvestri C; Pecorari L; Iacobucci I; Soverini S; Fasano T; Martinelli G; Cervantes F; Calabretta B
Leuk Res; 2007 Feb; 31(2):163-7. PubMed ID: 16797705
[TBL] [Abstract][Full Text] [Related]
28. [Quantification of the PRAME transcripts in patients with acute myeloid leukemia].
Zhu ZH; Qian J; Lin J; Yao DM; Qian Z; Wang YL; Chen Q; Han LX; Xiao G
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Apr; 27(2):149-52. PubMed ID: 20376794
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion.
Kim M; Jang HR; Kim JH; Noh SM; Song KS; Cho JS; Jeong HY; Norman JC; Caswell PT; Kang GH; Kim SY; Yoo HS; Kim YS
Carcinogenesis; 2008 Mar; 29(3):629-37. PubMed ID: 18283041
[TBL] [Abstract][Full Text] [Related]
30. [Detecting methylation of the calcitonin gene in monitoring treatment and disease evolution for myelogenous leukemia].
Xie XH; Chen ZZ; Zhang XM; Huang MQ
Ai Zheng; 2003 Jun; 22(6):616-9. PubMed ID: 12948412
[TBL] [Abstract][Full Text] [Related]
31. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
32. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
33. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.
Yamada N; Nishida Y; Tsutsumida H; Hamada T; Goto M; Higashi M; Nomoto M; Yonezawa S
Cancer Res; 2008 Apr; 68(8):2708-16. PubMed ID: 18413738
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation does not regulate JUNB expression in CML: comment on "Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia" by Hoshino et al. [Leuk. Res. 33 (2009) 1361-1366].
Strathdee G; Ferguson S; Sim A; Brown R
Leuk Res; 2010 May; 34(5):685-6. PubMed ID: 20006998
[No Abstract] [Full Text] [Related]
35. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
36. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation.
Campo Dell'Orto M; Banelli B; Giarin E; Accordi B; Trentin L; Romani M; te Kronnie G; Basso G
Oncol Rep; 2007 Aug; 18(2):417-23. PubMed ID: 17611665
[TBL] [Abstract][Full Text] [Related]
38. Survivin expression in chronic myeloid leukemia.
Conte E; Stagno F; Guglielmo P; Scuto A; Consoli C; Messina A
Cancer Lett; 2005 Jul; 225(1):105-10. PubMed ID: 15922862
[TBL] [Abstract][Full Text] [Related]
39. Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity.
Guarcello V; Blanquicett C; Naguib FN; El Kouni MH
Cancer Chemother Pharmacol; 2008 Jun; 62(1):85-96. PubMed ID: 17805539
[TBL] [Abstract][Full Text] [Related]
40. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.
Bao F; Polk P; Nordberg ML; Veillon DM; Sun A; Deininger M; Murray D; Andersson BS; Munker R
Leuk Res; 2007 Nov; 31(11):1511-20. PubMed ID: 17403535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
